Phase II Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Patients With Advanced Solid Tumors (KEYNOTE 158)
Summary
NOTE: This trial has limited slots available.
Only the Microsatellite Instability (MSI)-High (MSI-H) solid tumor cohort is open for patients with pancreatic cancer.
The purpose of this phase II trial is to determine the effectiveness of pembrolizumab in patients with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy and to further evaluate its safety.
Biomarker testing will be done during screening for the trial.
General Information
NCT#: NCT02628067
Study ID: 3475-158
Trial Phase: Phase II
Trial Sponsor: Merck Sharp & Dohme Corp.
Therapies Used in This Trial: Pembrolizumab